Access in Dialysis for Better Outcomes in Patient Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-29

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multi-center health economic study in Canada. Participants will be randomly assigned to receive either the study or control dialysis catheter. The primary objective is to evaluate resource utilization in Ontario related to hemodialysis catheter placement including tissue plasminogen activator (tPA) usage, catheter exchange rates, catheter patency, and missed dialysis days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improving the Outcomes of Peritoneal Dialysis (PD) Catheter Insertion

NCT04034628

Peritoneal Dialysis Access Failure Peritoneal Dialysis Complication

UNKNOWN

Symptom Management in Patients on Dialysis

NCT05515991

End-stage Kidney Disease

ACTIVE_NOT_RECRUITING NA

Efficacy and Safety of Repeated-use Middle Cut Off Membrane Dialyzers in Hemodialysis Patients

NCT06950944

Hemodialysis Hemodialysis Treatment Dialysis Adequacy

COMPLETED NA

Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit

NCT03172039

End Stage Renal Failure on Dialysis Infection, Bacterial

COMPLETED

Cohort Study Comparing Short Daily Hemodialysis (HD) With Conventional HD

NCT00182156

End-stage Renal Disease Thrombocytopathy Cardiovascular Diseases

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Venous Catheter Catheter-Related Bloodstream Infection (CRBSI) Nos

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care Device

Current standard of care polyurethane catheter used at the hospital

Group Type OTHER

Standard of Care Catheter

Intervention Type DEVICE

Study Device

BioFlo DuraMax Chronic Hemodialysis Catheter

Group Type OTHER

BioFlo DuraMax Chronic Hemodialysis Catheter

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BioFlo DuraMax Chronic Hemodialysis Catheter

Intervention Type DEVICE

Standard of Care Catheter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is indicated for a dialysis catheter for the purpose of attaining long-term vascular access for hemodialysis. Long-term vascular access is defined by physician anticipated duration of hemodialysis for three months or longer.
* Is ≥ 18 years of age.
* Is indicated to receive dialysis treatment at a location where dialysis treatment data will be accessible by the study team.
* Is able to comprehend and have signed the Informed Consent Form (ICF) to participate in the study.

Exclusion Criteria

* Has known or suspected presence of other device-related infection, bacteremia, or septicemia or has been treated with antibiotics for documented or suspected infection within prior 45 days.
* Is receiving prophylactic anti-coagulation or anti-platelet pharmacotherapy for the purpose of central venous catheter (CVC) patency (anti-coagulation or anti-platelet pharmacotherapy for therapeutic indications do not exclude the patient from the study).
* Has severe chronic obstructive lung disease.
* Had past radiation therapy at the prospective insertion site.
* Had previous episodes of venous thrombosis or vascular surgical procedures at the prospective insertion site.
* Has local tissue factors that will prevent proper device stabilization and/or access.
* Has a stent placed in the vessel where the catheter will be placed
* Is pregnant
* History of drug or alcohol abuse in the past 12 months obtained from patient record and/or interview
* Subjects who weigh ≤ 30 kg.
* Has been previously enrolled in this clinical study, or is participating in another clinical study that is contraindicative to the treatment or outcomes of this investigation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No